PDUFA Negotiations End With Differences To Resolve In Commitment Letter
This article was originally published in The Tan Sheet & The Rose Sheet
The entire PDUFDA VI reauthorization process likely is more than a year from completion, but agreeing on a draft commitment letter is a major milestone for FDA and the pharma industry. It will serve as the foundation of the legislative phase expected to begin in early 2017.
You may also be interested in...
FDA and industry also talking about improvements to combination product review process as part of user fee program renewal.
Both ideas also will require more FDA expertise, agency tells industry.
FDA tells industry that proposal on trials also can’t use SPA-like process.